The Insider Kenneth Hoberman Sold 14040 shares of Stemline Therapeutics, Inc. (STML); Garde Capital Lifted Apple Com (AAPL) Position By $1.20 Million

Garde Capital Inc increased Apple Inc Com (AAPL) stake by 33.79% reported in 2017Q3 SEC filing. Garde Capital Inc acquired 7,802 shares as Apple Inc Com (AAPL)’s stock rose 12.78%. The Garde Capital Inc holds 30,889 shares with $4.76M value, up from 23,087 last quarter. Apple Inc Com now has $900.87 billion valuation. The stock increased 1.03% or $1.81 during the last trading session, reaching $177.09. About 25.42M shares traded. Apple Inc. (NASDAQ:AAPL) has risen 62.48% since January 13, 2017 and is uptrending. It has outperformed by 45.78% the S&P500.

Recently, an insider trading trade was made. Kenneth Hoberman, the Chief Operating Officer and an insider of Stemline Therapeutics Inc unloaded exactly 14,040 shares of Stemline Therapeutics Inc, worth precisely $195,577 USD, at $13.9 for every share at the time of the trade. It seems he is very active lately as in the last month, he quietly unloaded additional 11,983 shares of the company, worth $169,942 USD. Kenneth Hoberman now owns 384,792 shares or 1.52% of Stemline Therapeutics Inc’s market cap. This transaction, which was filled on January 10, 2018 was disclosed in a document with the DC-based SEC.

Analysts await Stemline Therapeutics, Inc. (NASDAQ:STML) to report earnings on March, 15. They expect $-0.67 EPS, down 19.64% or $0.11 from last year’s $-0.56 per share. After $-0.68 actual EPS reported by Stemline Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -1.47% EPS growth.

Since December 15, 2017, it had 0 insider buys, and 1 insider sale for $169,942 activity. Hoberman Kenneth had sold 11,983 shares worth $169,942.

Investors sentiment increased to 1.24 in Q3 2017. Its up 0.24, from 1 in 2017Q2. It is positive, as 6 investors sold Stemline Therapeutics, Inc. shares while 19 reduced holdings. 13 funds opened positions while 18 raised stakes. 12.54 million shares or 4.36% more from 12.02 million shares in 2017Q2 were reported. State Street owns 349,585 shares. Victory Cap owns 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 1,858 shares. Pura Vida Invests Ltd Liability, a New York-based fund reported 60,000 shares. D E Shaw And accumulated 87,294 shares. Manufacturers Life Insur The, Ontario – Canada-based fund reported 19,499 shares. California Public Employees Retirement Sys accumulated 0% or 31,100 shares. Moreover, Schwab Charles Inv Mngmt has 0% invested in Stemline Therapeutics, Inc. (NASDAQ:STML). Sei Communications reported 130 shares. C World Group Holding A S owns 0.03% invested in Stemline Therapeutics, Inc. (NASDAQ:STML) for 160,000 shares. Axa holds 0.03% or 620,546 shares. Metropolitan Life Ins Company invested in 0% or 15,763 shares. Art Ltd Liability Corp holds 16,038 shares. Sabby Management reported 43,749 shares. Royal Bank & Trust Of Canada, Ontario – Canada-based fund reported 5,089 shares. State Of Wisconsin Invest Board invested in 0% or 16,000 shares.

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics in the United States. The company has market cap of $356.55 million. The firm develops SL-401, a targeted therapy directed to the interleukin-3 receptor , which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It currently has negative earnings. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.

Among 4 analysts covering Stemline Therapeutics Inc (NASDAQ:STML), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Stemline Therapeutics Inc has $38.0 highest and $11 lowest target. $24.25’s average target is 71.99% above currents $14.1 stock price. Stemline Therapeutics Inc had 12 analyst reports since November 10, 2015 according to SRatingsIntel. On Friday, June 23 the stock rating was maintained by Cowen & Co with “Buy”. H.C. Wainwright maintained the stock with “Buy” rating in Friday, November 10 report. Cowen & Co maintained Stemline Therapeutics, Inc. (NASDAQ:STML) on Wednesday, June 14 with “Buy” rating. H.C. Wainwright maintained the shares of STML in report on Thursday, December 14 with “Buy” rating. Jefferies maintained Stemline Therapeutics, Inc. (NASDAQ:STML) rating on Monday, June 26. Jefferies has “Buy” rating and $1600 target. H.C. Wainwright maintained Stemline Therapeutics, Inc. (NASDAQ:STML) rating on Tuesday, September 12. H.C. Wainwright has “Buy” rating and $34.0 target. H.C. Wainwright maintained the shares of STML in report on Wednesday, November 1 with “Buy” rating. The firm has “Buy” rating given on Monday, June 26 by H.C. Wainwright. The firm earned “Outperform” rating on Monday, February 6 by Wedbush. The firm earned “Buy” rating on Wednesday, August 9 by H.C. Wainwright.

The stock increased 1.81% or $0.25 during the last trading session, reaching $14.1. About 100,595 shares traded. Stemline Therapeutics, Inc. (NASDAQ:STML) has risen 52.65% since January 13, 2017 and is uptrending. It has outperformed by 35.95% the S&P500.

Investors sentiment increased to 0.7 in Q3 2017. Its up 0.02, from 0.68 in 2017Q2. It increased, as 52 investors sold AAPL shares while 1034 reduced holdings. 116 funds opened positions while 640 raised stakes. 2.97 billion shares or 2.78% less from 3.06 billion shares in 2017Q2 were reported. Union Natl Bank Corp holds 2.57% or 49,583 shares in its portfolio. S R Schill And Associate owns 7,120 shares. Comml Bank Of Nova Scotia reported 1.13M shares. 16,927 are owned by Baker Ellis Asset Mngmt Ltd Liability. Weatherstone Mngmt invested in 5,390 shares. The Massachusetts-based Fernwood Investment Management Ltd Liability has invested 1.23% in Apple Inc. (NASDAQ:AAPL). Muhlenkamp Inc reported 147,401 shares. Leavell Invest Mgmt accumulated 100,355 shares. Credit Suisse Ag reported 1.52% of its portfolio in Apple Inc. (NASDAQ:AAPL). Aureus Asset Limited Liability Company holds 95,653 shares. Envestnet Asset Mgmt owns 740,706 shares or 0.27% of their US portfolio. Aristotle Limited Co owns 4,000 shares. Private Advisor Group Incorporated Ltd Limited Liability Company reported 571,191 shares. Edge Wealth Management Ltd Liability Com holds 4.76% of its portfolio in Apple Inc. (NASDAQ:AAPL) for 102,376 shares. State Common Retirement Fund holds 15.07M shares or 2.97% of its portfolio.